Shares Magazine
0.78p+0.00 (+0.00%)18 Apr 2024, 10:28
Jump to:
Evgen Pharma PLC Fundamentals
| Company Name | Evgen Pharma PLC | Last Updated | 2024-04-18 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 427.347 m | Market Cap | £3.31 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.1055 | Cash Equity Ratio | 0.9474 |
| Quick Ratio | 10.3855 | Current Ratio | 10.39 |
| Price To Book Value | 0.8417 | ROCE | 0 |
Evgen Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Evgen Pharma PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £3,000.00 | £5,000.00 | £5,000.00 |
| Intangible Assets | £43,000.00 | £53,000.00 | £66,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £46,000.00 | £58,000.00 | £71,000.00 |
| Stocks | 0 | 0 | 0 |
| Debtors | £43,000.00 | £13,000.00 | £16,000.00 |
| Cash & Equivalents | £5.00 m | £9.03 m | £11.59 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £6.17 m | £9.64 m | £12.42 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £833,000.00 | £411,000.00 | £607,000.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £833,000.00 | £411,000.00 | £607,000.00 |
| Net assets | £5.34 m | £9.23 m | £11.81 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £687,000.00 | £687,000.00 | £687,000.00 |
| Share Premium | £27.87 m | £27.87 m | £27.87 m |
| Profit / Loss | -£5.01 m | -£3.17 m | -£3.21 m |
| Other Equity | £5.34 m | £9.23 m | £11.81 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £5.34 m | £9.23 m | £11.81 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.1055 | 1.1055 | 1.1055 |
| Cash / Equity | 0.9474 | 0.9474 | 0.9474 |
| EPS | -£0.01 | -£0.01 | -£0.02 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£4.13 m | -£2.58 m | -£2.93 m |
| Cashflow before financing | 0 | 0 | £7.47 m |
| Increase in Cash | £490,000.00 | -£1.08 m | £1.46 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £442,000.00 | 0 | £194,000.00 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£5.10 m | -£3.19 m | -£3.21 m |
| Pre-Tax profit | -£5.01 m | -£3.17 m | -£3.21 m |
Evgen Pharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage. |
| Latest Interim Date | 31 Oct 2023 |
| Latest Fiscal Year End Date | 7 Jun 2023 |
Evgen Pharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-04-05 | Dr. Huw Jones | Executive Director,Chief Executive Officer |
| 2024-04-05 | Dr. Susan Elizabeth Foden | Non-Executive Director,Chairman (Interim) and Senior Independent Director |
| 2017-06-23 | Mr. John Bradshaw | Executive Director,Finance Director and Company Secretary |
| 2020-04-30 | Dr. Stephen Joseph Franklin | Executive Director,Chief Executive Officer |
| 2023-06-20 | Mr. Richard Anthony Moulson | Executive Director,Chief Financial Officer |
| 2017-04-03 | Dr. Mark Andrew Wyatt | Non-Executive Director |
| 2023-09-05 | Mr. Barry Clare | Executive Director,Chairman |
| 2018-11-08 | Dr. Marc Francois d’Abbadie | Non-Executive Director |
| 2023-06-20 | Dr. Alan John Barge | Non-Executive Director |
| 2023-12-28 | Ms. Susan Elizabeth Clement-Davies | Non-Executive Director |
| 2024-04-05 | Mr. Toni Markus Antero Hanninen | Executive Director,Chief Financial Officer |
Evgen Pharma PLC Contact Details
| Company Name | Evgen Pharma PLC |
|---|---|
| Address | Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, L3 5RF |
| Telephone | |
| Website | https://www.evgen.com |
Evgen Pharma PLC Advisors
| Auditor | RSM UK Audit LLP |
|---|---|
| Phone | +44 1516002600 |
| Remuneration Consultant | PricewaterhouseCoopers LLP |
|---|---|
| Phone | +44 205835000 |
| Fax | +44 208224652 |
| Stockbroker | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Registrar | S.L.C Registrars Ltd |
|---|---|
| Phone | +44 1903706150 |
| Nominated Adviser | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Financial PR Adviser | Buchanan |
|---|---|
| Phone | +44 2074665000 |
| Fax | +44 2074665001 |
| Solicitor | Pinsent Masons LLP |
|---|---|
| Phone | +44 2074187000 |
| Fax | +44 2074187050 |
| Solicitor | Theobald Associates |
|---|---|
| Phone | +44 2073978434 |
| Fax | +44 2073978400 |
| Stockbroker | Stockdale Securities Ltd |
|---|---|
| Phone | +44 2076016100 |
| Nominated Adviser | Stockdale Securities Ltd |
|---|---|
| Phone | +44 2076016100 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Hipgnosis Songs Fund Limited | 91.40 | 29.65 |
| Wizz Air Holdings PLC | 2,080.00 | 4.68 |
| Dr. Martens PLC | 70.00 | 4.48 |
| International Consolidated Airlines Group S.A. | 167.90 | 4.48 |
| Wood Group (John) PLC | 148.85 | 3.95 |
| Spire Healthcare Group PLC | 246.50 | 3.35 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Rentokil Initial PLC | 411.60 | -7.90 |
| Dunelm Group PLC | 1,007.00 | -6.24 |
| Future PLC | 629.44 | -4.70 |
| Watches Of Switzerland Group PLC | 334.00 | -4.46 |
| Vesuvius PLC | 457.00 | -3.79 |
| Quilter PLC | 99.00 | -3.41 |